Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Social Psychiatry and Psychiatric Epidemiology
Published in: Social Psychiatry and Psychiatric Epidemiology 1/2016

01-01-2016 | Invited Review

Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health

Authors: S. M. Cotton, K. M. Filia, A. Ratheesh, K. Pennell, S. Goldstone, P. D. McGorry

Published in: Social Psychiatry and Psychiatric Epidemiology | Issue 1/2016

Login to get access

Abstract

Background

Specialised early intervention (SEI) programs have offered individuals with psychotic disorders and their families new hope for improving illness trajectories and outcomes. The Early Psychosis Prevention and Intervention Centre (EPPIC) was one of the first SEI programs developed in the world, providing services for young people experiencing their first episode of psychosis.

Methods

We conducted a narrative synthesis of controlled and uncontrolled studies that have been conducted at EPPIC.

Discussion

The history of the EPPIC model is first described. This is followed by a discussion of clinical research emerging from EPPIC, including psychopharmacological, psychotherapeutic trials and outcome studies. Neurobiological studies are also described. Issues pertaining to the conduct of clinical research and future research directions are then described. Finally, the impact of the EPPIC model on the Australian environment is discussed.
Literature
1.
McGorry PD, Edwards J (1998) The feasibility and effectiveness of early intervention in psychotic disorders: the Australian experience. Int Clin Psychopharmcol 13(supp 1):S47–S52CrossRef
2.
Edwards J, McGorry PD (2002) Implementing early intervention in psychosis: a guide to establishing early psychosis services. Martin Dunitz Ltd, LondonCrossRef
3.
4.
Phillips LJ, Leicester SB, O’Dwyer LE, Francey SM, Koutsogiannis J, Abdel-Baki A, Kelly D, Jones S, Vay C, Yung AR, McGorry PD (2002) The PACE clinic: identification and management of young people at ‘ultra’ high risk of psychosis. Psychiatr Pract 8:255–269CrossRef
5.
Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, McGorry PD (2003) Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res 60:21–32PubMedCrossRef
6.
Yung AR, Phillips LJ, Yuen HP, McGorry PD (2004) Risk factors for psychosis in ultra high-risk group: psychopathology and clinical features. Schizophr Res 67:131–142PubMedCrossRef
7.
Phillips LJ, Yung AR, McGorry PD (2000) Identification of young people at risk of psychosis: validation of personal assessment and crisis evaluation clinic intake criteria. Aust N Z J Psychiatry 34:S164–S169PubMedCrossRef
8.
Yung A, McGorry PD, McFarlane CA, Patton GC (1995) The PACE clinic: development of a clinical service for young people at high risk of psychosis. Australas Psychiatry 3:345–349CrossRef
9.
Yung A, McGorry PD, McFarlane CA, Jackson H, Patton GC, Rakkar A (1996) Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 22:283–303PubMedCrossRef
10.
McGorry PD, Yung A, Phillips LJ (2003) The “close in” or ultra-high-risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr Bull 29:771–790PubMedCrossRef
11.
Yung AR, Yuen HP, Berger G, Francey S, Hung TC, Nelson B, Phillips L, McGorry P (2007) Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 33:673–681PubMedCentralPubMedCrossRef
12.
Nelson B, Yuen HP, Wood SJ, Lin A, Spiliotacopoulos D, Bruxner A, Broussard C, Simmons M, Foley DL, Brewer WJ, Francey SM, Amminger GP, Thompson A, McGorry PD, Yung AR (2013) Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: The PACE 400 study. JAMA Psychiatry 70:793–802PubMedCrossRef
13.
Wiltink S, Velthorst E, Nelson B, McGorry PM, Yung AR (2015) Declining transition rates to psychosis: the contribution of potential changes in referral pathways to an ultra-high-risk service. Early Interv Psychiatry 9:200–206PubMedCrossRef
14.
Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, Yung AR, Bullmore ET, Brewer WJ, Soulsby B, Desmond P, McGuire PK (2003) Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361:281–288PubMedCrossRef
15.
McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlrd S, Jackson H (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928PubMedCrossRef
16.
Phillips LJ, McGorry PD, Yuen HP, Ward J, Donovan K, Kelly D, Francey SM, Yung AR (2007) Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 96:25–33PubMedCrossRef
17.
Phillips LJ, Nelson B, Yuen HP, Francey SM, Simmons M, Stanford C, Ross M, Kelly D, Baker K, Conus P, Amminger GP, Trumpler F, Yun Y, Lim McNab C, Yung A, McGorry PD (2009) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 43:818–829PubMedCrossRef
18.
Yung AR, Phillips LJ, Nelson B, Francey SM, Yuen HP, Simmons MB, Ross ML, Kelly D, Baker K, Amminger GP, Berger G, Thompson AD, Thampi A, McGorry PD (2011) Randomized controlled trial of intervention for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry 72:430–440PubMedCrossRef
19.
McGorry PD, Nelson B, Phillips LJ, Yuen HP, Francey SM, Thampi A, Berger GE, Amminger GP, Simmons MB, Kelly D, Thompson AD, Yung AR (2013) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve month outcomes. J Clin Psychiatry 74:349–356PubMedCrossRef
20.
Pantelis C, Yucel M, Wood SJ, Velakoulis D, Sun D, Berger G, Stuart GW, Yung AR, Phillips LJ, McGorry P (2005) Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull 31(3):672–696PubMedCrossRef
21.
Berger GE, Wood SJ, Ross M, Hamer CA, Wellard RM, Pell G, Phillips L, Nelson B, Amminger GP, Yung AR, Jackson GD, Velakoulis D, Pantelis C, Manji H, McGorry PD (2012) Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis: a longitudinal MRI/MRS study. Curr Pharm Des 18:570–575PubMedCrossRef
22.
Markulev C, McGorry PD, Nelson B, Yuen HP, Schaefer M, Yung AR, Thompson A, Berger G, Mossaheb N, Schlögelhofer M, Smesny S, de Haan L, Riecher-Rössler A, Nordentoft M, Chen EY, Verma S, Hickie I, Amminger GP (2015) NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Interv Psychiatry. doi:10.​1111/​eip.​12260
23.
Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE (2010) Long-chain {omega}-3 fatty acids for indicated prevention of psychotic disorders: a randomized placebo-controlled trial. Arch Gen Psychiatry 67(2):146–154. doi:10.​1001/​archgenpsychiatr​y.​2009.​192 PubMedCrossRef
24.
McGlashan T (1999) Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 46:899–907PubMedCrossRef
25.
Birchwood M, Connor C, Lester H, Patterson P, Freemantle N, Marshall M, Fowler D, Lewis S, Jones P, Amos T, Everard L, Singh SP (2013) Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. Br J Psychiatry 203:58–64PubMedCrossRef
26.
McGorry PD (1995) A treatment-relevant classification of psychotic disorders. Aust N Z J Psychiatry 29:555–558PubMedCrossRef
27.
Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T (2005) Association between duration of untreated psychosis and outcome in cohorts of first-episode patients. Am J Psychiatry 157:1183–1188
28.
Malla A, Bechard-Evans L, Joober R, King S, Albadi S (2006) Understanding the complexities of delay in treatment of psychosis and relevance for early detection interventions. Schizophr Res 86(Supp 1):S40CrossRef
29.
Lincoln TM (1995) Who cares? Pathways to psychiatric care for young people experiencing a first episode of psychosis. Psychiatr Serv 46:1166–1171PubMedCrossRef
30.
McGorry PD (2000) Evaluating the importance of reducing the duration of untreated psychosis. Aust N Z J Psychiatry 34:145–149CrossRef
31.
Apeldoorn SY, Sterk B, van den Heuvel ER, Schoevers RA, Islam MA, Bruggeman R, Cahn W, deHaan L, Kahn RS, Meijer CJ, Myin-Germeys I, van Os J, Wiersma D (2014) Factors contributing to the duration of untreated psychosis. Schizophr Res 158:76–81PubMedCrossRef
32.
Polari A, Lavoie S, Sarrasin P, Pellanda V, Cotton S, Conus P (2011) Duration of untreated psychosis: a proposition regarding treatment definition. Early Interv Psychiatry 5:301–308PubMedCrossRef
33.
Carbone S, Harrigan SM, McGorry PD, Curry C, Elkins K (1999) Duration of untreated psychosis and 12-month outcome in first-episode psychosis: the impact of treatment approach. Acta Psychiatr Scand 100:96–104PubMedCrossRef
34.
McGorry PD, Edwards J, Mihalopoulos C, Harrigan SM, Jackson HJ (1996) EPPIC: an evolving system for early detection and optimal management. Schizophr Bull 22(2):305–326PubMedCrossRef
35.
Crumlish N, Whitty P, Clarke M, Browne S, Kamali M, Gerven M, McTigue O, Kinsella A, Waddington JL, Larkin C, O’Callaghan E (2009) Beyond the critical period: longitudinal study of 8-year outcome in non-affective first episode psychosis. Br J Psychiatry 194:18–24PubMedCrossRef
36.
Harrigan SM, McGorry PD, Krstev H (2003) Does treatment delay in first-episode psychosis really matter? Psychol Med 33:97–110PubMedCrossRef
37.
Schimmelmann BG, Huber CG, Lambert M, Cotton S, McGorry PD, Conus P (2008) Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res 42(12):982–990PubMedCrossRef
38.
Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, Prosser AL, Jackson HJ, McGorry PD (2005) The relationship between duration of untreated psychosis and outcome: an eight year prospective study. Schizophr Res 79(1):85–93PubMedCrossRef
39.
McGlashan T (1996) Early detection and intervention of schizophrenia: research. Schizophr Bull 22:327–345PubMedCrossRef
40.
Power P, Iacoponi E, Reynolds N, Fisher H, Garety PA, McGuire PK, Craig T (2007) The Lambeth Early Onset Crisis Assessment Team Study: general practitioner education and access to an early detection team in first episode psychosis. Br J Psychiatry 191(Supp 51):S133–S139CrossRef
41.
Lester H, Birchwood M, Freemantle N, Michail M, Tait L (2009) REDIRECT: cluster randomised controlled trial of GP training in first-episode psychosis. Br J Gen Pract 59:e183–e190PubMedCentralPubMedCrossRef
42.
Yung AR, Organ BA, Harris MG (2003) Management of early psychosis in a generic adult mental health service. Aust N Z J Psychiatry 37:429–436PubMedCrossRef
43.
Krstev H, Carbone S, Harrigan SM, Curry C, Elkin K, McGorry PD (2004) Early intervention in first-episode psychosis: the impact of a community development campaign. Soc Psychiatry Psychiatr Epidemiol 39:711–719PubMedCrossRef
44.
Melle I, Larsen TK, Haahr U, Friss S, Johannessen J, Opjordsmoen S, Simonsen E, Rund BR, Vaglum P, McGlashan T (2004) Reducing the duration of untreated first-episode psychosis. Arch Intern Med 61:143–150
45.
Joa I, Johannessen J, Ausestad B, Friis S, McGlashan T, Melle I, Opjordsmoen S, Simonsen E, Vaglum P, Larsen TK (2008) The key to reducing duration of untreated psychosis: information campaigns. Schizophr Bull 34:466–472PubMedCentralPubMedCrossRef
46.
Chong SA, Mythily S, Verma S (2005) Reducing the duration of untreated psychosis and changing help-seeking behaviour in Singapore. Soc Psychiatry Psychiatr Epidemiol 40:619–621PubMedCrossRef
47.
Malla A, Norman EL, Scholten D, Manchanda R, McLean T (2005) A community intervention for early identification of first-episode psychosis: impact on duration of untreated psychosis (DUP) and patient characteristics. Soc Psychiatry Psychiatr Epidemiol 40:337–344PubMedCrossRef
48.
Lloyd-Evans B, Crosby M, Stockton S, Pilling S, Hobbs L, Hinton M, Johnson S (2011) Initiatives to shorten duration of untreated psychosis: systematic review. Br J Psychiatry 198:256–263PubMedCrossRef
49.
Melle I, Johannesen JO, Friis S, Haahr U, Joa I, Larsen TK, Opjordsmoen S, Rund BR, Simonsen E, Vaglum MacGlashan TH (2006) Early detection of the first episode of schizophrenia and suicidal behaviour. Am J Psychiatry 163:800–804PubMedCrossRef
50.
International Early Psychosis Association Writing Group (2005) International clinical practice guidelines for early psychosis. Br J Psychiatry 187(Supp 48):s120–s124CrossRef
51.
Lehtinen V, Aaltonen J, Koffett T, Räkköläinen V, Syvälahti E (2000) Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? Eur Psychiatry 15:312–320PubMedCrossRef
52.
Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765–1773PubMedCentralPubMedCrossRef
53.
Britvic D, Maric NP, Doknic M, Pekic S, Andric S, Jasovic-Gasic M, Popovic V (2013) Metabolic issues in psychotic disorders with the focus on first-episode patients: a review. Psychiatr Dunubina 25:410–415
54.
Schultz SC, Thomson R, Brecher M (2003) The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy. Schizophr Res 62:1–12CrossRef
55.
Arvantis LA, Miller BG (1997) Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42:233–246CrossRef
56.
Berger G, Proffitt TM, McConchie M, Kerr M, Markulev C, Yuen HP, O’Donnell C, Lubman D, Polari A, Wood SJ, Amminger GP, McGorry PD (2008) Dosing quetiapine in drug-naive first episode psychosis: a controlled, double-blind, randomized, single-centre study investigating efficacy, tolerability and safety of 200 mg/day vs. 400 mg/day of quetiapine fumarate in 141 patients aged 15 to 25 years. J Clin Psychiatry 69:1702–1714PubMedCrossRef
57.
McGorry PD, Cocks J, Power P, Burnett P, Harrigan S, Lambert T (2011) Very-low dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment. Schizophr Res Treat 2011:631690
58.
Edwards J, Maude D, McGorry PD, Harrigan SM, Cocks JT (1998) Six-month clinical status as a predictor of 24-month clinical outcome in first-admission patients with schizophrenia. Br J Psychiatry 172:107–116
59.
Hermann-Doig T, Maude D, Edwards J (2003) Systematic treatment of persistent psychosis (STOPP): a psychological approach to facilitating recovery in young people with first episode psychosis. Martin Dunitz, London
60.
Edwards J, Cocks J, Burnett P, Maud D, Wong L, Yuen HP, Harrigan SM, Hermann-Doig T, Murphy B, Wade D, McGorry PD (2011) Randomized controlled trial of clozapine and CBT for first-episode psychosis with enduring positive symptoms: a pilot study. Schizophr Res Treat 2011:394896
61.
Berger GE, Smensy S, Amminger GP (2006) Bioactive lipids in schizophrenia. Int Rev Psychiatry 18:85–98PubMedCrossRef
62.
Reddy RD, Keshavan MS, Yao JK (2004) Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr Bull 30:901–911PubMedCrossRef
63.
Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP (2003) Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53:56–64PubMedCrossRef
64.
Khan MM, Evans DR, Gunna V, Scheffer RE, Parikh W, Mahadik SP (2002) Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never medicated first episode of psychosis and after years of treatments with antipsychotics. Schizophr Res 58:1–10PubMedCrossRef
65.
Berger GE, Proffitt TM, McConchie M, Yuen HP, Wood SJ, Amminger GP, Brewer WJ, McGorry PD (2007) Ethyl-eicosapentaenoic acid in first episode psychosis: a randomised, placebo-controlled trial. J Clin Psychiatry 68:1867–1875PubMedCrossRef
66.
67.
Tarrier N, Khan S, Cater J, Picken A (2007) The subjective consequences of suffering a first episode psychosis: trauma and suicide behaviour. Soc Psychiatry Psychiatr Epidemiol 42:29–35PubMedCrossRef
68.
69.
Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J (2001) The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 50:884–897PubMedCrossRef
70.
Birchwood M, Todd P, Jackson C (1998) Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry 172(33):53–59
71.
Penn DL, Waldeter EJ, Perkins DO, Mueser KT, Lieberman JA (2005) Psychosocial treatment for first episode psychosis: a research update. Am J Psychiatry 162:2220–2232PubMedCrossRef
72.
Jackson H, McGorry P, Edwards J, Hulbert C, Henry L, Francey S, Maude D, Cocks J, Power P, Harrigan S, Dudgeon P (1998) Cognitively-oriented psychotherapy for early psychosis (COPE): preliminary results. Br J Psychiatry 172:93–100
73.
Jackson H, McGorry P, Edwards J, Hulbert C (1996) Cognitively oriented psychotherapy for early psychosis (COPE). In: Cotton P, Jackson H (eds) Early intervention and prevention in mental health. Australian Psychological Society, Melbourne, pp 131–154
74.
Jackson H, McGorry P, Edwards J, Hulbert C, Henry L, Harrigan S, Dudgeon P, Francey S, Maude D, Cocks J, Killackey E, Power P (2005) A controlled trial of cognitively oriented psychotherapy for early psychosis (COPE) with four-year follow-up readmission data. Psychol Med 35:1295–1306PubMedCrossRef
75.
Jackson HJ, McGorry PD, Killackey E, Bendall S, Allott K, Dudgeon P, Gleeson J, Johnson T, Harrigan S (2008) Acute-phase and 1-year follow-up results of a randomised controlled trial of CBT versus Befriending for first episode psychosis: the ACE project. Psychol Med 38:725–735PubMedCrossRef
76.
Drury V, Birchwood M, Cochrane R, Macmillian F (1996) Cognitive therapy and recovery from acute psychosis: a controlled trial. I. Impact on positive symptoms. Br J Psychiatry 169:593–607PubMedCrossRef
77.
Robinson DG, Woerner MG, Delman HM, Kane JM (2005) Pharmacological treatment for first-episode schizophrenia. Schizophr Bull 31:705–722PubMedCrossRef
78.
Wiersma D, Nienhuis FJ, Slooff CJ, Giel R (1998) Natural course of schizophrenic disorders: a 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 24:75–85PubMedCrossRef
79.
Gumley A, O’Grady M, McNay L, Reilly J, Power K, Norrie J (2003) Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. Psychol Med 33:419–431PubMedCrossRef
80.
Hogarty GE, Greenwald D, Ulrich RF, Kornblith SJ, DiBarry AL, Cooley S, Carter M, Flesher S (1997) Three-year trials of personal therapy among schizophrenic patients living with or independent of family, pt 2: effects of adjustment of patients. Am J Psychiatry 154:1514–1524PubMedCrossRef
81.
Gleeson J, Wade D, Castles D, Gee D, Crisp K, Pearce T, Newman B, Cotton S, Alvarez-Jimenez M, Gilbert M, McGorry P (2008) The Episode II trial of cognitive and family therapy for relapse prevention in early psychosis: rationale and sample characteristics. J Ment Health 17(1):19–32CrossRef
82.
Gleeson JFM, Cotton S, Alvarez-Jimenez M, Wade D, Gee D, Crisp K, Newman B, Spiliotacopoulous D, McGorry PD (2009) A randomized controlled trial of CBT for relapse prevention for remitted first-episode psychosis patients. J Clin Psychiatry 70(4):477–486PubMedCrossRef
83.
Falloon IRH (1988) Handbook of behavioral family therapy. The Guilford Press, New York
84.
Mueser KT, Glynn SM (1999) Behavioural family therapy for psychiatric disorders. New Harbinger, Oakland
85.
Zhang M, Wang M, Li J, Phillips LR (1994) Randomised-control trial of family intervention for 78 first episode male schizophrenic patients: an 18-month study in Suzhou, Jiangsu. Br J Psychiatry Suppl 165:96–102
86.
Gleeson JFM, Cotton SM, Alvarez-Jimenez M, Wade D, Gee D, Crisp K, Pearce T, Spiliotacopoulos D, Newman B, McGorry PD (2013) A randomised controlled trial of relapse prevention therapy for first episode psychosis patients: outcome at 30-month follow-up. Schizophr Bull 39:436–448PubMedCentralPubMedCrossRef
87.
Gleeson JFM, Cotton SM, Alvarez-Jimenez M, Wade D, Crisp K, Newman B, Spiliotacopoulos D, McGorry PD (2010) Family outcomes from an RCT of relapse prevention therapy in first episode psychosis. J Clin Psychiatry 71:475–483PubMedCrossRef
88.
Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 70:913–920PubMedCrossRef
89.
Sacaceno B, Levav I, Kohn R (2005) The public mental health significance of research on socioeconomic factors in schizophrenia and major depression. World Psychiatry 4:181
90.
Lund C, De Silva M, Plagerson S, Cooper S, Chisholm D, Das J, Knapp M, Patel V (2011) Poverty and mental disorders: breaking the cycle in low-income and middle-income countries. Lancet 378:1502–1514PubMedCrossRef
91.
Killackey E, Jackson HJ, Gleeson J, Hickie I, McGorry PD (2006) Exciting career opportunity beckons! Early intervention and vocational rehabilitation in first episode psychosis: employing cautious optimism. Aust N Z J Psychiatry 40:951–960PubMedCrossRef
92.
Killackey E, Jackson HJ, McGorry PD (2008) Vocational intervention in first episode psychosis: individual placement and support versus treatment as usual. Br J Psychiatry 193:114–120PubMedCrossRef
93.
Killackey E, Allott K, Cotton S, Jackson HJ, Scutella R, Tseng Y-P, Borland J, Proffitt TM, Hunt S, Kay-Lambkin F, Chinnery G, Baksheev G, Alvarez-Jimenez M, McGorry PD (2013) A randomized controlled trial of vocational intervention for young people with first-episode psychosis: method. Early Interv Psychiatry 7:329–337PubMedCrossRef
94.
Bartholomeusz CF, Allott K (2012) Neurocognitive and social cognitive approaches for improving functional outcome in early psychosis: theoretical considerations and current state of evidence. Schizophr Res Treat 2012:815315
95.
Bartholomeusz CF, Allott K, Killackey E, Liu P, Wood SJ, Thompson A (2013) Social cognition training as an intervention for improving functional outcome in first episode psychosis: a feasibility study. Early Interv Psychiatry 7:421–426PubMedCrossRef
96.
Wood SJ, Velakoulis D, Smith DJ, Bond D, Stuart GW, McGorry PD, Brewer WJ, Bridle N, Eritaia J, Desmond P, Singh B, Copolov D, Pantelis C (2001) A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophr Res 52:37–46PubMedCrossRef
97.
Takahashi T, Wood SJ, Soulsby B, Kawasaki Y, McGorry PD, Suzuki M, Velakoulis D, Pantelis C (2009) An MRI study of the superior temporal subregions in first-episode patients with various psychotic disorders. Schizophr Res 113:158–166PubMedCrossRef
98.
Pariante CM, Vassilopoulou K, Velakoulis D, Phillips L, Soulsby B, Wood SJ, Brewer W, Smith DJ, Dazzan P, Yung AR, Zervas IM, Christodoulou GN, Murray R, McGorry PD, Pantelis C (2004) Pituitary volume in psychosis. Br J Psychiatry 185:5–10PubMedCrossRef
99.
Brewer WJ, Wood SJ, McGorry PD, Francey SM, Phillips LJ, Yung AR, Anderson V, Copolov DL, Singh B, Velakoulis D, Pantelis C (2001) Stability of olfactory identification deficits in neuroleptic-naive patients with first-episode psychosis. Am J Psychiatry 158:107–115PubMedCrossRef
100.
Mathes B, Wood SJ, Proffitt TM, Stuart GW, Buchanan JA, Velakoulis D, Brewer WJ, McGorry PD, Pantelis C (2005) Early processing deficits in object working memory in first-episode schizophreniform psychosis and established schizophrenia. Psychol Med 35:1053–1062PubMedCrossRef
101.
Wood SJ, Tarnawski AU, Proffitt TM, Brewer WJ, Savage GR, Anderson V, McGorry PD, Velakoulis D, Pantelis C (2007) Fractionation of verbal memory impairment in schizophrenia and schizophreniform psychosis. Aust N Z J Psychiatry 41:732–739PubMedCrossRef
102.
Bartholomeusz CF, Proffitt TM, Savage G, Simpson L, Markulev C, Kerr M, McConchie M, McGorry PD, Pantelis C, Berger GE, Wood SJ (2011) Relational memory in first episode psychosis: implications for progressive hippocampal dysfunction after illness onset. Aust N Z J Psychiatry 45:206–213PubMedCrossRef
103.
Takahashi T, Wood SJ, Soulsby B, McGorry PD, Tanino R, Suzuki M, Velakoulis D, Pantelis C (2009) Follow-up MRI study of the insular cortex in first-episode psychosis and chronic schizophrenia. Schizophr Res 108:49–56PubMedCrossRef
104.
Fornito A, Yücel M, Wood SJ, Adamson C, Velakoulis D, Saling MM, McGorry PD, Pantelis C (2008) Surface-based morphometry of the anterior cingulate cortex in first episode schizophrenia. Hum Brain Mapp 29:478–489PubMedCrossRef
105.
Walterfang M, Wood AG, Reutens DC, Wood SJ, Chen J, Velakoulis D, McGorry PD, Pantelis C (2008) Morphology of the corpus callosum at different stages of schizophrenia: cross-sectional study in first-episode and chronic illness. Br J Psychiatry 192:429–434PubMedCrossRef
106.
Sun D, Stuart GW, Jenkinson M, Wood SJ, McGorry PD, Velakoulis D, van Erp TG, Thompson PM, Toga AW, Smith DJ, Cannon TD, Pantelis C (2009) Brain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Mol Psychiatry 14:976–986PubMedCentralPubMedCrossRef
107.
Velakoulis D, Wood SJ, McGorry PD, Pantelis C (2000) Evidence for progression of brain structural abnormalities in schizophrenia: beyond the neurodevelopmental model. Aust N Z J Psychiatry 34:S113–S126PubMedCrossRef
108.
Velakoulis D, Wood SJ, Wong MT, McGorry PD, Yung A, Phillips L, Smith D, Brewer W, Proffitt T, Desmond P, Pantelis C (2006) Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 63:139–149PubMedCrossRef
109.
Wood SJ, Proffitt TM, Mahony K, Smith DJ, Buchanan JA, Brewer WJ, Stuart GW, Velakoulis D, McGorry PD, Pantelis C (2002) Visuospatial memory and learning in first-episode schizophreniform psychosis and established schizophrenia: a functional correlate of hippocampal pathology? Psychol Med 32:429–438PubMedCrossRef
110.
Harrison BJ, Yücel M, Shaw M, Brewer WJ, Nathan PJ, Strother SC, Olver JS, Egan GF, Velakoulis D, McGorry PD, Pantelis C (2006) Dysfunction of dorsolateral prefrontal cortex in antipsychotic-naïve schizophreniform psychosis. Psychiatry Res Neuroimaging 148:23–31PubMedCrossRef
111.
Yücel M, Brewer WJ, Harrison BJ, Fornito A, O’Keefe GJ, Olver J, Scott AM, Egan GF, Velakoulis D, McGorry PD, Pantelis C (2007) Anterior cingulate activation in antipsychotic-naive first-episode schizophrenia. Acta Psychiatr Scand 115:155–158PubMedCrossRef
112.
Cocchi L, Walterfang M, Testa R, Wood SJ, Seal ML, Suckling J, Takahashi T, Proffitt TM, Brewer WJ, Adamson C, Soulsby B, Velakoulis D, McGorry PD, Pantelis C (2009) Grey and white matter abnormalities are associated with impaired spatial working memory ability in first-episode schizophrenia. Schizophr Res 115:163–172PubMedCrossRef
113.
Nicolo JP, Berger GE, Garner BA, Velakoulis D, Markulev C, Kerr M, McGorry P, Proffitt TM, McConchie M, Pantelis C, Wood SJ (2010) The effect of atypical antipsychotics on pituitary gland volume in patients with first-episode psychosis: a longitudinal MRI study. Schizophr Res 116:49–54PubMedCrossRef
114.
Brewer WJ, Yücel M, Harrison BJ, McGorry PD, Oliver J, Egan GF, Velakoulis D, Pantelis C (2007) Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Aust N Z J Psychiatry 41:129–135PubMedCrossRef
115.
Wood SJ, Berger GE, Wellard RM, Proffitt T, McConchie M, Velakoulis D, McGorry PD, Pantelis C (2008) A 1H-MRS investigation of the medial temporal lobe in antipsychotic-naïve and early-treated first episode psychosis. Schizophr Res 102:163–170PubMedCrossRef
116.
Murphy BP, Pang TY, Hannan AJ, Proffitt TM, McConchie M, Kerr M, Markulev C, O’Donnell C, McGorry PD, Berger GE (2014) Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis. Schizophr Res Treat 2014:719395
117.
Berger G, Wood SJ, Wellard RW, Proffitt TM, McConchie M, Amminger GP, Jackson GD, Velakoulis D, Pantelis C, McGorry PD (2008) Ethyl-eicosapentaenoic acid in first episode psychosis. A 1H-MRS study. Neuropsychopharmacology 33:2467–2473PubMedCrossRef
118.
Wood SJ, Cocchi L, Proffitt TM, McConchie M, Jackson GD, Takahashi T, Pantelis C, McGorry P, Berger GE (2010) Neuroprotective effects of ethyl-eicosapentaenoic acid in first episode psychosis: a longitudinal T2 relaxometry pilot study. Psychiatry Res Neuroimaging 182:180–182PubMedCrossRef
119.
Pantelis C, Yücel M, Wood SJ, McGorry PD, Velakoulis D (2003) Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust N Z J Psychiatry 37:399–406PubMedCrossRef
120.
Pantelis C, Wood SJ, Proffitt TM, Mahony K, Brewer WJ, Buchanan JA, Velakoulis D, McGorry PD (2009) Attentional set-shifting ability in first-episode and established schizophrenia: relationship to working memory. Schizophr Res 112:104–113PubMedCrossRef
121.
Phillips LJ, McGorry PD, Garner B, Thompson KN, Pantelis C, Wood SJ, Berger G (2006) Stress, the hippocampus and the hypothalamic–pituitary–adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry 40:725–741PubMedCrossRef
122.
McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ (2006) Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 40:616–622PubMedCrossRef
123.
McGorry PD, Nelson B, Goldstone S, Yung AR (2010) Clinical staging: a heuristic and practical strategy for new research and better health and social outcomes for psychotic and related mood disorders. Can J Psychiatry 55:486–497PubMed
124.
Scott J, Leboyer M, Hickie I, Berk M, Kapczinski F, Frank E, Kupfer D, McGorry P (2013) Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. Br J Psychiatry 202:243–245PubMedCrossRef
125.
McGorry PD, Yung A, Phillips L (2001) Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 51:17–29PubMedCrossRef
126.
Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, de Haan L (2011) Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res 132:8–17PubMedCrossRef
127.
McGorry PD (2002) Consensus on early intervention in schizophrenia. Schizophr Bull 132:8–17
128.
Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, Fraser R, Hughes F, Crisp K, Harrigan S, Wood SJ, Berk M, McGorry PD (2010) Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res 119:1–10PubMedCrossRef
129.
Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Bush AI (2008) N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry 64:361–368PubMedCrossRef
130.
Iseger TA, Bossong MG (2015) A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res 162:153–161PubMedCrossRef
131.
Penn D, Waldeter EJ, Perkins DO, Mueser KT, Lieberman JA (2005) Psychosocial treatment for first-episode psychosis: a research update. Am J Psychiatry 162:2220–2232PubMedCrossRef
132.
Jackson H, McGorry P, Henry L, Edwards J, Hulbert C, Harrigan S, Dudgeon P, Francey S, Maude D, Cocks J, Power P (2001) Cognitively oriented psychotherapy for early psychosis (COPE): a 1-year follow-up. Br J Clin Psychol 40:57–70PubMedCrossRef
133.
Gleeson J, Wade D, Albiston D, Castle D, Gilbert M, Gee D, Crisp K, Pearce T, Newman B, Cotton S, Young D, McGorry P (2005) Preventing EPISODE II: relapse prevention n first-episode psychosis. Australias Psychiatry 13:384–387CrossRef
134.
Stavely H, Hughes F, Pennell K, McGorry PD, Purcell R (2013) EPPIC model implementation guide. Orygen Youth Health Research Centre, Melbourne
135.
Alvarez-Jimenez M, Bendall S, Lederman R, Wadley G, Chinnery G, Vargas S, Larkin M, Killackey E, McGorry PD, Gleeson JF (2013) On the HORYZON: moderated online social therapy for long-term recovery in first episode psychosis. Schizophr Res 143:143–149PubMedCrossRef
136.
Birchwood M, Fiorillo A (2000) The critical period for early intervention. Psychiatr Rehabil Skills 4:182–198CrossRef
137.
Purcell R, Goldstone S, Moran J, Albiston D, Edwards J, Pennell K, McGorry PD (2011) Toward a twenty-first century approach to youth mental health care. Int J Ment Health 40:72–87CrossRef
138.
Kane JM, Schooler NR, Marcy P, Correll CU, Brunette MF, Mueser KT, Rosenheck R, Addington J, Estroff SE, Robinson J, Penn DL, Robinson DG (2015) The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. J Clin Psychiatry 76:240–246PubMedCrossRef
Metadata
Title
Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health
Authors
S. M. Cotton
K. M. Filia
A. Ratheesh
K. Pennell
S. Goldstone
P. D. McGorry
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Social Psychiatry and Psychiatric Epidemiology / Issue 1/2016
Print ISSN: 0933-7954
Electronic ISSN: 1433-9285
DOI
https://doi.org/10.1007/s00127-015-1140-0

Other articles of this Issue 1/2016

Social Psychiatry and Psychiatric Epidemiology 1/2016 Go to the issue

Original Paper

Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study

Original Paper

The prevalence of mental disorders among upper primary school children in Kenya

Original Paper

Child mental health and maternal depression history in Pakistan

Original Paper

Functional impairment and mental health functioning among Vietnamese children

Original Paper

The accuracy of suicide statistics: are true suicide deaths misclassified?

Erratum

Erratum to: Correlates of victimisation amongst people with psychosis